.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Deloitte
Argus Health
Colorcon
AstraZeneca
Mallinckrodt
US Department of Justice
Queensland Health
Chubb
Moodys

Generated: June 28, 2017

DrugPatentWatch Database Preview

NALFON Drug Profile

« Back to Dashboard

Which patents cover Nalfon, and what generic Nalfon alternatives are available?

Nalfon is a drug marketed by Xspire and Dista and is included in two NDAs.

The generic ingredient in NALFON is fenoprofen calcium. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the fenoprofen calcium profile page.

Summary for Tradename: NALFON

Patents:0
Applicants:2
NDAs:2
Suppliers / Packagers: see list9
Bulk Api Vendors: see list93
Clinical Trials: see list1
Patent Applications: see list6,489
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NALFON at DailyMed

Pharmacology for Tradename: NALFON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xspire
NALFON
fenoprofen calcium
CAPSULE;ORAL017604-003Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe
Dista
NALFON
fenoprofen calcium
TABLET;ORAL017710-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Xspire
NALFON
fenoprofen calcium
CAPSULE;ORAL017604-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Xspire
NALFON
fenoprofen calcium
CAPSULE;ORAL017604-004Jul 21, 2009RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NALFON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Xspire
NALFON
fenoprofen calcium
CAPSULE;ORAL017604-003Approved Prior to Jan 1, 19823,600,437► Subscribe
Dista
NALFON
fenoprofen calcium
TABLET;ORAL017710-001Approved Prior to Jan 1, 19823,600,437► Subscribe
Xspire
NALFON
fenoprofen calcium
CAPSULE;ORAL017604-002Approved Prior to Jan 1, 19823,600,437► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Daiichi Sankyo
Fuji
Baxter
Dow
Cerilliant
Medtronic
Merck
Johnson and Johnson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot